Maxcyte annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Maxcyte Capital Expenditures (CapEx) Growth & History (MXCT)
Maxcyte's capital expenditures (capex) was $1.8M for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.8M | $117,000 | +7.09% |
| 2024 | 2024-12-31 | $1.7M | −$2.0M | −55.38% |
| 2023 | 2023-12-31 | $3.7M | −$14.8M | −79.98% |
| 2022 | 2022-12-31 | $18.5M | $14.6M | +381.90% |
| 2021 | 2021-12-31 | $3.8M | $1.8M | +85.04% |
| 2020 | 2020-12-31 | $2.1M | $800,800 | +62.99% |
| 2019 | 2019-12-31 | $1.3M | — | — |
Maxcyte quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $62,000 | −$522,000 | −89.38% |
| Q1 2026 | 2026-03-31 | $72,000 | −$581,000 | −88.97% |
| Q4 2025 | 2025-12-31 | $231,000 | $84,000 | +57.14% |
| Q3 2025 | 2025-09-30 | $300,000 | −$106,000 | −26.11% |
| Q2 2025 | 2025-06-30 | $584,000 | $290,000 | +98.64% |
| Q1 2025 | 2025-03-31 | $653,000 | −$151,000 | −18.78% |
| Q4 2024 | 2024-12-31 | $147,000 | −$768,000 | −83.93% |
| Q3 2024 | 2024-09-30 | $406,000 | −$314,000 | −43.61% |
| Q2 2024 | 2024-06-30 | $294,000 | −$213,000 | −42.01% |
| Q1 2024 | 2024-03-31 | $804,000 | −$754,000 | −48.40% |
| Q4 2023 | 2023-12-31 | $915,000 | −$1.3M | −58.30% |
| Q3 2023 | 2023-09-30 | $720,000 | −$2.8M | −79.30% |
| Q2 2023 | 2023-06-30 | $507,000 | −$6.3M | −92.55% |
| Q1 2023 | 2023-03-31 | $1.6M | −$4.4M | −74.03% |
| Q4 2022 | 2022-12-31 | $2.2M | $1.1M | +95.55% |
| Q3 2022 | 2022-09-30 | $3.5M | $2.0M | +141.35% |
| Q2 2022 | 2022-06-30 | $6.8M | $5.8M | +606.97% |
| Q1 2022 | 2022-03-31 | $6.0M | $5.7M | +1844.73% |
| Q4 2021 | 2021-12-31 | $1.1M | — | — |
| Q3 2021 | 2021-09-30 | $1.4M | $777,550 | +117.21% |
| Q2 2021 | 2021-06-30 | $962,600 | — | — |
| Q1 2021 | 2021-03-31 | $308,500 | — | — |
| Q3 2020 | 2020-09-30 | $663,400 | — | — |
Maxcyte capital expenditures (capex) trends
Over the last five fiscal years, Maxcyte's capital expenditures (capex) decreased from $2.1M to $1.8M, a change of −$304,100. The latest reported quarter, Q2 2026, shows $62,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗